WuXi Biologics has secured GMP certification from the UK MHRA for two Wuxi-based sites—Drug Product Facility 5 (DP5) and the Drug Product Packaging Center (DPPC)—enabling commercial production of an ophthalmic biologic. Over a four-day inspection with zero critical findings, both sites demonstrated robust quality systems. DP5, the company’s inaugural commercial pre-filled syringe facility, and DPPC, which offers fully traceable packaging services, join WuXi’s global network that now exceeds 100 million fill-finish units per year across liquid, lyophilized and combination products. As of year-end 2025, WuXi Biologics has passed 46 regulatory inspections—including 22 by FDA and EMA—holds 136 facility licenses and maintains a 100% success rate in FDA Pre-License Inspections, underscoring its leadership in compliance and manufacturing scale.

The newly unveiled PatroLab™ platform integrates real-time Raman PAT monitoring with predictive in-silico modeling to create digital twins of bioprocesses. By tracking over 40 critical performance and quality attributes and increasing batch data density nearly 1,000-fold versus traditional methods, the system accelerates quality-by-design workflows and minimizes development timelines. PatroLab™ enables “what-if” scenario analysis for root-cause identification and risk mitigation during scale-up, reduces batch deviation and rejection rates through model-predictive control, and supports real-time release testing in line with FDA and EMA guidance. Embedded within WuXi’s digital ecosystem, the platform fosters cross-team collaboration via unified data visualization, trend analysis and automated alerts, driving efficiency and consistency in commercial biologics manufacturing.